Other, smaller trials in patients who already have Alzheimers point both ways, with Edison et al reporting better executive scores and less temporal and whole-brain atrophy on liraglutide, while Gejl (n=38, 6 mo follow-up) and Mullins (n=21, 1.5 yrs follow-up) were neutral to negative, which is exactly what you expect from studies that are short, and not powered to read a slow, insidious disease
For example, clinical trials found that participants taking 2.4 mg of semaglutide lost almost twice as much weight as those on 1.0 mg
Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use
For Canadian researchers and consumers following the Retatrutide pipeline, these results are particularly significant because they strengthen the case for eventual Health Canada regulatory review, which will likely follow the FDA submission timeline
Possible Chiari malformation or increased intracranial pressure